Tesamorelin vs Ipamorelin: Mechanism and Dosing Compared

Tesamorelin and ipamorelin both come up in research discussions of growth hormone, but tesamorelin vs ipamorelin is a comparison across two different receptor pathways, not two versions of the same mechanism. One has a current FDA-approved formulation; the other has none. This reference lines up what separates tesamorelin and ipamorelin and what stays identical in the reconstitution math. It is written for research and educational purposes only and is not medical advice.

What separates tesamorelin and ipamorelin

The difference is mechanism, not potency. Tesamorelin is a stabilized analog of the full 44-amino acid growth hormone-releasing hormone (GHRH) molecule and acts on the GHRH receptor, prompting the pituitary to release growth hormone directly. Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor, a separate pathway that also triggers growth hormone release. Because the two compounds work through different receptors, their effects are commonly described in the research literature as additive rather than redundant — the same rationale that underlies pairing a GHRH analog like CJC-1295 with ipamorelin in a single research protocol.

Ipamorelin has no GHRH-receptor activity of its own, and tesamorelin has no secretagogue activity on the ghrelin receptor — each compound works through exactly one of the two pathways, not both. That separation is also why the two are compared to each other rather than treated as interchangeable options within the same mechanism. Reconstitution and storage handling don't change based on any of this: both peptides arrive as lyophilized powder and dissolve the same way once bacteriostatic water is added.

Regulatory and research status

This is the sharpest difference between tesamorelin and ipamorelin. Tesamorelin has a current FDA-approved pharmaceutical formulation, marketed as Egrifta and Egrifta SV, indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval reflects completed human trials for that specific indication, and the labeling is publicly available through DailyMed. Ipamorelin has no FDA-approved formulation for any indication and remains a research compound studied in preclinical and limited early human research.

That distinction doesn't mean ipamorelin is untested, and it doesn't mean tesamorelin's approval extends past its one cleared use. Outside that specific indication, tesamorelin is discussed here strictly as research chemistry, the same as ipamorelin — neither compound is covered in this article as a use recommendation.

Vial formats and typical concentrations

Both peptides reach researchers as lyophilized powder in single-peptide vials, most often at these reference points:

Peptide	Common vial size	Reference water volume	Concentration
Tesamorelin	10 mg	2 mL	5 mg/mL
Ipamorelin	5 mg	2 mL	2.5 mg/mL

These are reference points because they land typical research doses on clean syringe marks, not because the arithmetic requires them. The peptide calculator recalculates concentration and units for any vial size and water volume you enter, for either compound.

Worked example: same formula, different receptor targets

The formula doesn't change based on which peptide, or which receptor pathway, is in the vial: concentration equals mass divided by water volume, and syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe.

Tesamorelin. A 10 mg vial with 2 mL of bacteriostatic water is 10 ÷ 2 = 5 mg/mL. A 1 mg dose is 1 ÷ 5 = 0.2 mL, or 0.2 × 100 = 20 units.

Ipamorelin. A 5 mg vial with 2 mL of bacteriostatic water is 5 ÷ 2 = 2.5 mg/mL. A 0.3 mg dose is 0.3 ÷ 2.5 = 0.12 mL, or 0.12 × 100 = 12 units.

Each figure depends entirely on the vial's own mass and water volume — the tesamorelin result says nothing about what the ipamorelin draw will be. Change either vial's water volume and only that compound's units shift.

Why one calculator covers both

Here's how we see it: the step where a research dose actually goes wrong isn't the injection, it's the reconstitution math. A U-100 insulin syringe always reads 100 units per mL, so the mg-per-unit depends entirely on how much water went into the vial — a fact that holds whether the vial contains tesamorelin or ipamorelin. Get the water volume wrong and every draw after inherits the same error, regardless of which receptor pathway the peptide targets. That's why a single calculator built on the mass-divided-by-volume formula covers both compounds without any peptide-specific adjustment. For the full mixing walkthrough, see how to reconstitute peptides.

Where the comparison breaks down

Tesamorelin vs ipamorelin is really a mechanism comparison, not a potency one, and that's where it breaks down if you push it too far. The reconstitution math is identical; the compounds and their regulatory histories are not. Tesamorelin's approved dosing schedule for its cleared indication came out of completed human trials specific to that molecule and that one use — it says nothing about ipamorelin, which has no approved formulation at all. And because tesamorelin and ipamorelin act on separate receptors rather than the same one, a dosing frequency referenced for one doesn't transfer to the other by default. Treating the two as swappable because they're both discussed in growth-hormone research, or assuming ipamorelin inherits any part of tesamorelin's approval status, are the two most common mix-ups in how this comparison gets discussed.

Common mistakes

The mistakes below come up repeatedly whenever tesamorelin vs ipamorelin gets discussed as a straight substitution instead of a comparison across receptors.

• Assuming ipamorelin shares tesamorelin's FDA approval. It doesn't. Tesamorelin's approval covers one specific indication for the tesamorelin molecule; ipamorelin has no approved formulation for any use.
• Treating the two as substitutes because both raise growth hormone. They reach that outcome through separate receptors, and a research protocol built around one doesn't automatically transfer to the other.
• Confusing mg and mcg. Tesamorelin and ipamorelin doses are described in milligrams or micrograms depending on the source. 1 mg equals 1,000 mcg, and misreading one for the other produces a 1,000x error.
• Shaking the vial. Swirl gently instead — shaking can degrade the peptide.
• Reusing a water volume across vial sizes. A water volume that gives 5 mg/mL for a 10 mg tesamorelin vial gives a different concentration on a 20 mg or 30 mg vial. Recalculate rather than reusing a number from memory.
• Assuming a dosing frequency from one compound applies to the other. Tesamorelin's approved schedule was established for that specific molecule and indication. It says nothing about an appropriate frequency for ipamorelin, whose research dosing is discussed separately in the literature.

Related

For the tesamorelin-specific reconstitution walkthrough, see the tesamorelin reconstitution calculator guide. For ipamorelin paired with a GHRH analog rather than compared against one, see CJC-1295 vs Ipamorelin. Or enter your own vial size, water volume, and target dose directly into the peptide dosage calculator to see the exact syringe units for either compound.